Eversept Partners, LP reported 105 positions worth $1.73B for the quarter ended Sep 30, 2026, down 5.6% on the prior quarter. It opened 20 new positions, added to 31, trimmed 48 and exited 29. Its largest holding is UNITED THERAPEUTICS Corp at 10.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| RVTY Revvity, Inc. | +366.2K | +437.9% | $55.98M | 3.97% |
| GH Guardant Health, Inc. | +256.4K | – | $45.74M | 2.64% |
| WAT Waters Corp | +75.4K | – | $33.14M | 1.91% |
| GRAL GRAIL, Inc. | +182.2K | – | $25.52M | 1.47% |
| OHI Omega Healthcare Investors Inc | +525.0K | +108.6% | $24.31M | 2.7% |
| ENSG Ensign Group, Inc | +124.1K | +20.6% | $21.35M | 7.21% |
| UTHR UNITED THERAPEUTICS Corp | +37.1K | +12.9% | $20.08M | 10.16% |
| ABVX Abivax S.A. | +186.8K | +20.4% | $18.49M | 6.29% |
| GDRX GoodRx Holdings, Inc. | +5.02M | – | $16.51M | 0.954% |
| ROIV Roivant Sciences Ltd. | +419.1K | – | $15.33M | 0.885% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| GSK GSK plc | -481.8K | -100.0% | $25.26M | Exited |
| IONS Ionis Pharmaceuticals Inc | -543.0K | -81.7% | $24.24M | 0.314% |
| LLY ELI LILLY & Co | -20.1K | -100.0% | $24.13M | Exited |
| TVTX Travere Therapeutics, Inc. | -345.1K | -43.2% | $20.32M | 1.54% |
| CLDX Celldex Therapeutics, Inc. | -611.2K | -34.2% | $19.81M | 2.2% |
| NTRA Natera, Inc. | -47.7K | -27.1% | $19.71M | 3.06% |
| AMN Amn Healthcare Services Inc | -428.5K | -100.0% | $13.87M | Exited |
| VRDN Viridian Therapeutics, Inc.DE | -650.9K | -78.3% | $13.40M | 0.214% |
| CELC Celcuity Inc. | -127.9K | -100.0% | $13.38M | Exited |
| HCA HCA Healthcare, Inc. | -29.9K | -30.5% | $12.77M | 1.68% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| GH Guardant Health, Inc. | +256.4K | $45.74M | 2.64% |
| WAT Waters Corp | +75.4K | $33.14M | 1.91% |
| GRAL GRAIL, Inc. | +182.2K | $25.52M | 1.47% |
| GDRX GoodRx Holdings, Inc. | +5.02M | $16.51M | 0.954% |
| ROIV Roivant Sciences Ltd. | +419.1K | $15.33M | 0.885% |
| SUPN Supernus, Inc. | +347.9K | $14.97M | 0.865% |
| ARWR Arrowhead Pharmaceuticals, Inc. | +156.2K | $10.22M | 0.59% |
| SMMT Summit Therapeutics Inc. | +526.6K | $8.91M | 0.514% |
| BNTX BioNTech SE | +61.7K | $6.06M | 0.35% |
| ABCL AbCellera Biologics Inc. | +254.1K | $3.71M | 0.214% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| GSK GSK plc | -481.8K | $25.26M | 1.38% |
| LLY ELI LILLY & Co | -20.1K | $24.13M | 1.32% |
| AMN Amn Healthcare Services Inc | -428.5K | $13.87M | 0.756% |
| CELC Celcuity Inc. | -127.9K | $13.38M | 0.73% |
| HUM Humana Inc | -31.2K | $12.38M | 0.675% |
| ASND Ascendis Pharma A/S | -41.6K | $11.10M | 0.605% |
| MRNA Moderna, Inc. | -152.1K | $10.65M | 0.581% |
| DFTX Definium Therapeutics, Inc. | -217.2K | $10.22M | 0.557% |
| CMPS COMPASS Pathways plc | -672.8K | $9.52M | 0.519% |
| NVO Novo Nordisk A S | -169.2K | $8.11M | 0.442% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS Corp | Healthcare | 324.7K | $175.97M | 10.16% | +37.1K | +12.9% | Added | 0.76% |
| 2 | EHC Encompass Health Corp | Healthcare | 1.08M | $131.49M | 7.59% | +55.4K | +5.4% | Added | 1.1% |
| 3 | ENSG Ensign Group, Inc | Healthcare | 726.2K | $124.90M | 7.21% | +124.1K | +20.6% | Added | 1.24% |
| 4 | ABVX Abivax S.A. | Healthcare | 1.10M | $108.99M | 6.29% | +186.8K | +20.4% | Added | 1.38% |
| 5 | VERA Vera Therapeutics, Inc. | Healthcare | 2.36M | $76.27M | 4.4% | +149.2K | +6.7% | Added | 3.27% |
| 6 | RVTY Revvity, Inc. | Healthcare | 449.8K | $68.77M | 3.97% | +366.2K | +437.9% | Added | 0.4% |
| 7 | NTRA Natera, Inc. | Healthcare | 128.1K | $52.96M | 3.06% | -47.7K | -27.1% | Reduced | 0.09% |
| 8 | CTRE CareTrust REIT, Inc. | Real Estate | 1.35M | $49.48M | 2.86% | +280.6K | +26.2% | Added | 0.53% |
| 9 | OHI Omega Healthcare Investors Inc | Real Estate | 1.01M | $46.71M | 2.7% | +525.0K | +108.6% | Added | 0.33% |
| 10 | SNDX Syndax Pharmaceuticals Inc | Healthcare | 2.44M | $45.93M | 2.65% | -355.2K | -12.7% | Reduced | 2.71% |
| 11 | GH Guardant Health, Inc. | Healthcare | 256.4K | $45.74M | 2.64% | +256.4K | – | New | 0.19% |
| 12 | CLDX Celldex Therapeutics, Inc. | Healthcare | 1.17M | $38.07M | 2.2% | -611.2K | -34.2% | Reduced | 1.5% |
| 13 | WAT Waters Corp | Healthcare | 75.4K | $33.14M | 1.91% | +75.4K | – | New | 0.08% |
| 14 | VKTX Viking Therapeutics, Inc. | Healthcare | 1.01M | $32.81M | 1.89% | +403.4K | +66.9% | Added | 0.79% |
| 15 | BKD Brookdale Senior Living Inc. | Healthcare | 2.87M | $31.05M | 1.79% | -529.3K | -15.6% | Reduced | 1.2% |
Tip. Select a row to see that position’s full history at Eversept Partners.
As of its Q3 2026 13F filing, Eversept Partners, LP’s five largest positions were UNITED THERAPEUTICS Corp (UTHR) at 10.2%, Encompass Health Corp (EHC) at 7.6%, Ensign Group, Inc (ENSG) at 7.2%, Abivax S.A. (ABVX) at 6.3%, Vera Therapeutics, Inc. (VERA) at 4.4% of the reported portfolio.
Eversept Partners, LP reported a 13F portfolio worth $1.73B across 105 positions for Q3 2026. That is down 5.6% from the previous quarter.
Its largest purchases by value were Revvity, Inc. ($55.98M), Guardant Health, Inc. ($45.74M), Waters Corp ($33.14M). It opened 20 new positions.
Its largest sales by value were GSK plc ($25.26M), Ionis Pharmaceuticals Inc ($24.24M), ELI LILLY & Co ($24.13M). It exited 29 positions entirely.
From the Form 13F-HR reports Eversept Partners, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.